Status:
COMPLETED
The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration
Lead Sponsor:
Ruth M. Rothstein CORE Center
Collaborating Sponsors:
Health Resources and Services Administration (HRSA)
The New York Academy of Medicine
Conditions:
HIV Infections
AIDS
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this study is to develop and evaluate an innovative model of care to better serve patients who are both HIV-infected and opioid-dependent.
Detailed Description
Hypothesis: HIV, opioid dependent patients provided agonist therapy at the site of their primary care will have better retention, utilization of services, health, social and quality of care measures a...
Eligibility Criteria
Inclusion
- 18 years or older
- Patient of the CORE Center
- HIV-infected (confirmed by HIV assay results)
- Opioid-dependent (by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision \[DSM-IV-TR\] criteria)
- Fluent in English or Spanish
- Planning to stay in Chicago area for the next 12 months
Exclusion
- Liver function tests (LFTs) (transaminase only) at 5 times or higher than normal
- DSM-IV-TR criteria for benzodiazepine abuse or dependence within the past 6 months
- DSM-IV-TR criteria for alcohol dependence within the past 6 months or actively suicidal
- Psychiatric impairment that impedes ability to consent
- Methadone dose exceeds level allowing for safe transition to buprenorphine
- Pregnant women or women actively trying to become pregnant
- Clinical judgement that patient is inappropriate for medical or psychiatric reasons
Key Trial Info
Start Date :
July 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT00227357
Start Date
July 1 2005
End Date
December 1 2008
Last Update
June 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The CORE Center
Chicago, Illinois, United States, 60612